Hemab Therapeutics Director Receives 36,000-Share Option

The option vests in equal monthly installments through September 24, 2029, subject to continuous service.

Available on EDGAR 09/25/2026 - 04:46 PM EDT Accepted by SEC EDGAR 09/25/2026 - 04:45 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Hemab Therapeutics Holdings, Inc. director Walbert Keli received a stock option award covering 36,000 shares of common stock on September 24, 2026. The exercise price is $35.72 per share, and the resulting option position covers 36,000 underlying shares. The option vests in equal monthly installments over three years, from September 24, 2026 through September 24, 2029, subject to continuous service, and expires September 23, 2036. No Rule 10b5-1 plan is reported.

Insider Trade Summary

Grant/Award: 36,000 shares

Grant/Award 1 txn

Insider Walbert Keli

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy) F1	36,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 36,000 options (Direct)

Footnotes (1)

1. F1. This option was granted on September 24, 2026. The shares underlying the option are scheduled to vest over three years in equal monthly installments from September 24, 2026 through September 24, 2029, subject to continuous service.

Key Figures

Option award: 36,000 underlying shares Exercise price: $35.72 per share Vesting period: Three years +1 more

4 metrics

Option award 36,000 underlying shares Granted September 24, 2026

Exercise price $35.72 per share Stock option

Vesting period Three years Equal monthly installments, subject to continuous service

Option expiration September 23, 2036 Stock option

Key Terms

Stock Option (Right to Buy), vest over three years, equal monthly installments, continuous service

4 terms

Stock Option (Right to Buy) financial

"Stock Option (Right to Buy)"

vest over three years financial

"scheduled to vest over three years"

equal monthly installments financial

"in equal monthly installments"

continuous service technical

"subject to continuous service"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock option did COAG director Walbert Keli receive?

Hemab Therapeutics Holdings, Inc. director Walbert Keli received an option covering 36,000 common shares on September 24, 2026, with an exercise price of $35.72 per share. The option expires September 23, 2036.

When does COAG director Walbert Keli's option vest?

The option vests in equal monthly installments over three years, from September 24, 2026 through September 24, 2029, subject to continuous service.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Walbert Keli

(Last) (First) (Middle)

C/O HEMAB THERAPEUTICS HOLDINGS, INC.

101 MAIN STREET, SUITE 1220

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Hemab Therapeutics Holdings, Inc. [ COAG ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/24/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$35.72	09/24/2026		A		36,000		(1)	09/23/2036	Common Stock	36,000	$0.00	36,000	D

Explanation of Responses:

1. This option was granted on September 24, 2026. The shares underlying the option are scheduled to vest over three years in equal monthly installments from September 24, 2026 through September 24, 2029, subject to continuous service.

	/s/ Mads Nikolaj Behrndt-Eriksen, as Attorney-in-Fact	09/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)